

C U R R I C U L U M V I T A E

Alessandro Dinoto (31/01/1990)

	PERSONAL DETAILS E-mail alessandro.dinoto@hotmail.it Skype alessandro.dinoto
CURRENT POSITION	PhD student, PhD in Neuroscience, Psychological and Psychiatric Sciences, and Movement Sciences - 37° ciclo (October 1, 2021 - September 30, 2024), University of Verona
PAST POSITIONS	Neurologia – Ospedale San Martino, Belluno AULSS 1 – Dolomiti Full-time Neurologist (from November 2020 to September 2021)
EDUCATION	Doctor of Medicine, University of Trieste (2015) <i>Magna cum laude</i> Neurology (specialty), University of Udine (2020) <i>Magna cum laude</i>
AREAS OF RESEARCH	Neuroimmunology Autoimmune encephalitis Multiple sclerosis Paraneoplastic neurological syndromes Atypical demyelinating disorders Inflammatory PNS disorders Clinical neurophysiology Neuropathology
INTERNATIONAL EXPERIENCES AND COLLABORATIONS	Oxford Autoimmune Neurology Group (tutor Prof. Sarosh Irani), clinical and laboratory experience focused on autoimmune encephalitis – December 2019-March 2020

PUBLICATIONS

1. Stragapede L, **Dinoto A**, Cheli M, Manganotti P. Epilepsia partialis continua following a Western variant tick-borne encephalitis. *J Neurovirol.* 2018 Dec;24(6):773-775. doi: 10.1007/s13365-018-0671-z.
2. **Dinoto A**, Busan P, Formaggio E, Bertolotti C, Menichelli A, Stokelj D, Manganotti P. Stuttering-like hesitation in speech during acute/post-acute phase of immune-mediated encephalitis. *J Fluency Disord.* 2018 Dec;58:70-76. doi: 10.1016/j.jfludis.2018.09.001.
3. Cheli M, **Dinoto A**, Ridolfi M, Sartori A, Stokelj D, Manganotti P. Motor neuron disease as a treatment responsive paraneoplastic neurological syndrome in patient with small cell lung cancer, anti-Hu antibodies and limbic encephalitis. *J Neurol Sci.* 2019 May 15;400:158-159. doi: 10.1016/j.jns.2019.03.024.
4. Morelli ME, Baldini S, Sartori A, D'Acunto L, **Dinoto A**, Bosco A, Bratina A, Manganotti P. Early putamen hypertrophy and ongoing hippocampus atrophy predict cognitive performance in the first ten years of relapsing-remitting multiple sclerosis. *Neurol Sci.* 2020 Apr 24. doi: 10.1007/s10072-020-04395-5.
5. Buoite Stella A, Pasquin F, Morrison SA, Morelli ME, **Dinoto A**, Bratina A, Bosco A, Sartori A, Giudici F, Manganotti P. Effects of a cooling vest with sham condition on walking capacity in heat-sensitive people with Multiple Sclerosis. *Eur J Appl Physiol.* 2020 Aug 20. doi: 10.1007/s00421-020-04478-3. Online ahead of print.
6. **Dinoto A**, Cheli M, Sartori A, Manganotti P. Comment on "Anti-NMDA receptor encephalitis presenting as new onset refractory status epilepticus in COVID-19". *Seizure.* 2020 Aug 13;81:166. doi:10.1016/j.seizure.2020.08.007.
7. Cheli M, **Dinoto A**, Olivo S, Tomaselli M, Stokelj D, Cominotto F, Brigo F, Manganotti P. SARS-CoV-2 pandemic and epilepsy: the impact on emergency department attendances for seizures. *Seizure.* 2020 Nov;82:23-26. doi: 10.1016/j.seizure.2020.08.008.
8. Cheli, M*, **Dinoto A***, Tommasini V, Ajčević M, Stella G, Catalan M, Stokelj D, Sartori A, Manganotti P. Rituximab efficacy on seizure control and cognitive symptoms in Leucine-rich, glioma-inactivated 1 (LGI1) limbic encephalitis: a high-density electroencephalography case study. *Epileptic Disord.* 2020 Oct 1;22(5):678-682. doi: 10.1684/epd.2020.1213.
*equally contributed.
9. **Dinoto A**, Bosco A, Sartori A, Bratina A, Bellavita G, Pasquin F, Cheli M, Manganotti P. Hiccups, severe vomiting and longitudinally extensive transverse myelitis in a patient with prostatic adenocarcinoma and Aquaporin-4 antibodies. *J Neuroimmunol.* 2021 Jan 20;352:577488. doi: 10.1016/j.jneuroim.2021.577488.

10. Sartori A, **Dinoto A**, Stragapede L, Mazzon G, Morelli ME, Pasquin F, Bratina A, Bosco A, Manganotti P. Nabiximols and botulinum toxin injections for patients with multiple sclerosis: efficacy on spasticity and spasms in a single-centre experience. *Neurol Sci.* 2021 Mar 19. doi: 10.1007/s10072-021-05182-6. Online ahead of print. PMID: 33742336
11. Olivo S, Cheli M, **Dinoto A**, Stokelj D, Tomaselli M, Manganotti P. Telemedicine during the SARS-Cov-2 pandemic lockdown: Monitoring stress and quality of sleep in patients with epilepsy. *Epilepsy Behav.* 2021 May;118:107864. doi: 10.1016/j.yebeh.2021.107864. Epub 2021 Feb 18.
12. **Dinoto A***, Cheli M*, Ajčević M, Dore F, Crisafulli C, Ukmar M, Sartori A, Manganotti P. ASL MRI and 18F-FDG-PET in autoimmune limbic encephalitis: clues from two paradigmatic cases. *Neurol Sci.* 2021 Mar 24. doi: 10.1007/s10072-021-05207-0. Online ahead of print.
*equally contributed.
13. **Dinoto A***, Cheli M*, Bratina A, Sartori A, Manganotti P. Bortezomib in anti-N-Methyl-d-Aspartate-Receptor (NMDA-R) encephalitis: A systematic review. *J Neuroimmunol.* 2021 Apr 28;356:577586. doi: 10.1016/j.jneuroim.2021.577586. Online ahead of print.
*equally contributed.
14. Manganotti P, Cheli M, **Dinoto A**, Biaduzzini F, Tomaselli M, Mazzon G, Roman-Pognuz E, Meletti S. Combining perampanel and ketamine in super refractory post-traumatic status epilepticus: A case report. *Seizure.* 2021 May 9;89:59-61. doi: 10.1016/j.seizure.2021.04.026. Online ahead of print.
15. **Dinoto A**, Baldini S, Morelli ME, Pasquin F, Bratina A, Bosco A, Sartori A, Manganotti P. Unveiling the relationship between autonomic involvement, fatigue, and cognitive dysfunction in early relapsing-remitting multiple sclerosis. *Neurol Sci.* 2021 Oct;42(10):4281-4287. doi: 10.1007/s10072-021-05487-6.
16. **Dinoto A**, Cheli M, Catalan M, Olivo S, Scali I, Bertolotti C, Sartori A, Manganotti P. Paraneoplastic neurological syndromes associated with non-Hodgkin lymphoma: a case series. *Neurol Sci.* 2022 Mar;43(3):2077-2079. doi: 10.1007/s10072-021-05801-2.
17. Dinoto A, Rossato F, Corradetti T, Gioulis M, Marsala SZ, Ferracci F. Multifocal nivolumab immune-related adverse effects during asymptomatic SARS-CoV-2 infection: causality or casuality? *Neurol Sci.* 2022 Jan 31:1-2. doi: 10.1007/s10072-022-05916-0.
18. Dinoto A, Sartori A, Cheli M, Pasquin F, Baldini S, Bratina A, Bosco A, Manganotti P. Lymphopenia during treatment with dimethyl fumarate in patients with multiple sclerosis: Prevalence,

	<p>predicting factors and clinical outcomes. Mult Scler Relat Disord. 2022 Jan;57:103357. doi: 10.1016/j.msard.2021.103357.</p> <p>19. Dinoto A*, Sechi E*, Ferrari S, Gajofatto A, Orlandi R, Solla P, Maccabeo A, Maniscalco GT, Andreone V, Sartori A, Manganotti P, Rasia S, Capra R, Mancinelli CR, Mariotto S. Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD. Mult Scler Relat Disord. 2022 Feb;58:103424. doi: 10.1016/j.msard.2021.103424. *equally contributed.</p> <p>20. Mariotto S, Carta S, Dinoto A, Lippi G, Salvagno GL, Masin L, Alberti D, Marignier R, Ferrari S. Is there a correlation between MOG-associated disorder and SARS-CoV-2 infection? Eur J Neurol. 2022 Feb 27. doi: 10.1111/ene.15304.</p> <p>21. Karteri S, Bruna J, Argyriou AA, Mariotto S, Velasco R, Alemany M, Kalofonou F, Alberti P, Dinoto A, Velissaris D, Stradella A, Cavaletti G, Ferrari S, Kalofonos HP. Prospectively Assessing Serum Neurofilament Light Chain Levels As A Biomarker Of Paclitaxel-Induced Peripheral Neurotoxicity In Breast Cancer Patients. J Peripher Nerv Syst. 2022 Apr 5. doi: 10.1111/jns.12493.</p> <p>22. Dinoto A, Sechi E, Flanagan EP, Ferrari S, Solla P, Mariotto S, Chen JJ. Serum and Cerebrospinal Fluid Biomarkers in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Associated Disease. Front Neurol. 2022 Mar 23;13:866824. doi: 10.3389/fneur.2022.866824.</p>		
<p>LANGUAGES (Common European Framework Of Reference For Languages)</p>	<p>English</p>	<p>German</p>	
<p>Reading</p>	<p>B2/C1</p>	<p>A1</p>	
<p>Writing</p>	<p>B2/C1</p>	<p>A1</p>	
<p>Speaking</p>	<p>B2/C1</p>	<p>A1</p>	